Celularity's Revenue Plummets, Losses Mount Amid Liquidity Crisis

TL;DR

**Celularity is bleeding cash and revenue, making it a high-risk bet with substantial doubt about its ability to continue as a going concern.**

AI Summary

Celularity Inc. reported a significant decline in total net revenues for the nine months ended September 30, 2025, falling to $22.446 million from $36.088 million in the same period of 2024, a decrease of 37.79%. This was primarily driven by a sharp drop in product sales, net, which plummeted from $26.199 million in 2024 to $12.291 million in 2025, a 53.1% reduction. The company's net loss widened substantially to $67.354 million for the nine months ended September 30, 2025, compared to a net loss of $44.599 million in the prior year, representing a 51.03% increase in losses. Operating expenses decreased slightly by 5.33% to $61.696 million from $65.166 million, mainly due to reduced selling, general and administrative expenses. However, other expenses surged, with a loss on debt extinguishment increasing from $3.908 million to $6.356 million, and a new loss on issuance of convertible note with warrants of $2.335 million. The company's cash and cash equivalents significantly decreased from $738 thousand at December 31, 2024, to $120 thousand at September 30, 2025, highlighting severe liquidity challenges. Total liabilities increased to $134.333 million from $123.845 million, while total stockholders' (deficit) equity deteriorated from $8.837 million to a deficit of $20.094 million.

Why It Matters

Celularity's substantial revenue decline and widening net losses signal significant operational and financial distress, directly impacting investor confidence and potentially jeopardizing future funding. The drastic reduction in cash and cash equivalents to just $120 thousand raises serious concerns about the company's ability to sustain operations, potentially leading to workforce reductions or asset liquidation. In a competitive biotech landscape, this financial instability could severely hinder Celularity's ability to develop and commercialize its cellular therapy candidates, allowing rivals to gain market share. Customers and employees face uncertainty regarding product availability and job security, respectively, as the company grapples with its going concern issues.

Risk Assessment

Risk Level: high — The company explicitly states, "There is substantial doubt about our ability to continue as a going concern," directly indicating severe financial instability. Cash and cash equivalents plummeted from $738 thousand at December 31, 2024, to $120 thousand at September 30, 2025, representing an 83.7% decrease in liquidity. Furthermore, the accumulated deficit grew to $967.101 million, underscoring persistent unprofitability.

Analyst Insight

Investors should avoid Celularity Inc. (CELUW) given the explicit 'going concern' warning, severe cash depletion to $120 thousand, and a 53.1% drop in product sales. Existing shareholders should consider divesting to mitigate further losses, as the company's financial health suggests a high probability of significant dilution or bankruptcy.

Financial Highlights

debt To Equity

N/A

revenue

$22.446 million

operating Margin

N/A

total Assets

N/A

total Debt

N/A

net Income

-$67.354 million

eps

N/A

gross Margin

N/A

cash Position

$120 thousand

revenue Growth

-37.79%

Revenue Breakdown

Key Numbers

• $22.446 million — Total net revenues (decreased from $36.088 million for the nine months ended September 30, 2024)
• $12.291 million — Product sales, net (decreased from $26.199 million for the nine months ended September 30, 2024)
• $67.354 million — Net loss (increased from $44.599 million for the nine months ended September 30, 2024)
• $120 thousand — Cash and cash equivalents (decreased from $738 thousand at December 31, 2024)
• $967.101 million — Accumulated deficit (increased from $899.683 million at December 31, 2024)
• $134.333 million — Total liabilities (increased from $123.845 million at December 31, 2024)
• $20.094 million — Total stockholders' (deficit) equity (deteriorated from $8.837 million at December 31, 2024)
• $6.356 million — Loss on debt extinguishment (increased from $3.908 million for the nine months ended September 30, 2024)
• $2.335 million — Loss on issuance of convertible note with warrants (new expense for the nine months ended September 30, 2025)
• 28,328,880 — Shares of Class A common stock outstanding (as of November 14, 2025)

Key Players & Entities

• Celularity Inc. (company) — registrant
• Nasdaq Stock Market LLC (regulator) — exchange for CELU and CELUW
• U.S. Food and Drug Administration (regulator) — regulatory approval process
• Center for Medicare & Medicaid Services (regulator) — rejection of Interfyl claims
• Yorkville (company) — debt extension and SEPA commitment fee
• RWI (company) — warrant issuance and modification
• C.V. Starr (company) — warrant issuance and modification
• Palantir (company) — settlement agreement
• Dragasac (company) — warrant repricing and inducement
• $120 thousand (dollar_amount) — cash and cash equivalents as of September 30, 2025

FAQ

Risk Factors

• Severe Liquidity Constraints [high — financial]: Cash and cash equivalents plummeted from $738 thousand at December 31, 2024, to $120 thousand at September 30, 2025. This severe reduction in liquidity poses a significant risk to the company's ability to meet its short-term obligations and fund ongoing operations.
• Worsening Net Loss and Accumulated Deficit [high — financial]: The net loss widened by 51.03% to $67.354 million for the nine months ended September 30, 2025, from $44.599 million in the prior year. The accumulated deficit increased to $967.101 million, indicating a persistent inability to generate profits.
• Increasing Liabilities and Negative Equity [high — financial]: Total liabilities increased to $134.333 million from $123.845 million, while total stockholders' equity deteriorated into a deficit of $20.094 million from a positive $8.837 million. This indicates a precarious financial position with liabilities significantly exceeding assets.
• Non-Operating Expense Increases [medium — financial]: Loss on debt extinguishment increased from $3.908 million to $6.356 million. Additionally, a new loss of $2.335 million on the issuance of convertible note with warrants was recorded, further pressuring profitability.
• Significant Revenue Decline [high — operational]: Total net revenues decreased by 37.79% to $22.446 million for the nine months ended September 30, 2025, down from $36.088 million in the same period of 2024. This sharp decline, particularly in product sales, signals potential issues with market demand or sales execution.

Industry Context

Celularity operates in the biotechnology and cell therapy sector, a highly competitive and capital-intensive industry. Companies in this space often face long development cycles, significant R&D costs, and stringent regulatory hurdles. Success is heavily dependent on clinical trial outcomes and the ability to secure ongoing funding.

Regulatory Implications

As a biotechnology company, Celularity is subject to rigorous oversight from regulatory bodies like the FDA. Delays in clinical trials, failure to meet efficacy or safety standards, or changes in regulatory requirements can significantly impact product development timelines and market access.

What Investors Should Do

1. Monitor cash burn rate and future financing activities.
2. Analyze the drivers of the significant revenue decline.
3. Evaluate the long-term viability given the negative equity and increasing liabilities.

Glossary

Loss on debt extinguishment

A loss recognized when a company repays or retires its debt before its scheduled maturity date, often due to refinancing at a lower interest rate or other financial restructuring. (This expense increased for Celularity, negatively impacting net income and indicating potential financial restructuring activities.)

Convertible note with warrants

A debt instrument that can be converted into shares of the issuer's stock, often issued with warrants, which give the holder the right to purchase additional shares at a specified price. (Celularity incurred a loss on the issuance of such a instrument, suggesting dilution or unfavorable terms for the company.)

Stockholders' (deficit) equity

The residual interest in the assets of an entity after deducting all its liabilities. A deficit means liabilities exceed assets. (Celularity's equity has turned into a significant deficit, highlighting a severe deterioration in its financial position.)

Year-Over-Year Comparison

Celularity Inc. has experienced a significant downturn compared to the prior year. Total net revenues have fallen by 37.79%, driven by a sharp 53.1% decrease in product sales. The company's financial health has deteriorated, with net losses widening by 51.03% and cash reserves dwindling to critically low levels. Furthermore, liabilities have increased while stockholders' equity has moved into a substantial deficit, indicating heightened financial risk.

Key Financial Figures

• $0.0001 — tered Class A Common Stock, par value $0.0001 per share CELU The Nasdaq Stock Mar
• $115 — A Common Stock at an exercise price of $115 per share CELUW The Nasdaq Stock Ma

Filing Documents

• form10-q.htm (10-Q) — 2560KB
• ex31-1.htm (EX-31.1) — 18KB
• ex31-2.htm (EX-31.2) — 18KB
• ex32-1.htm (EX-32.1) — 9KB
• ex32-2.htm (EX-32.2) — 9KB
• 0001493152-25-023467.txt ( ) — 14633KB
• celu-20250930.xsd (EX-101.SCH) — 123KB
• celu-20250930_cal.xml (EX-101.CAL) — 99KB
• celu-20250930_def.xml (EX-101.DEF) — 593KB
• celu-20250930_lab.xml (EX-101.LAB) — 843KB
• celu-20250930_pre.xml (EX-101.PRE) — 708KB
• form10-q_htm.xml (XML) — 2570KB

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 42 Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 52 Item 4.

Controls and Procedures

Controls and Procedures 52 PART II. OTHER INFORMATION Item 1.

Legal Proceedings

Legal Proceedings 53 Item 1A.

Risk Factors

Risk Factors 53 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 54 Item 3. Defaults Upon Senior Securities 55 Item 4. Mine Safety Disclosures 55 Item 5. Other Information 55 Item 6. Exhibits 55

Signatures

Signatures 56 Unless the context indicates otherwise, references in this quarterly report to the "Company," "Celularity," "we," "us," "our" and similar terms refer to Celularity Inc. and its consolidated subsidiaries. This quarterly report on Form 10-Q also contains registered marks, trademarks and trade names of other companies. Celularity Inc. has exclusive rights to the use of the Celularity logo, Celularity IMPACT, Biovance, Interfyl, Lifebank, CentaFlex and other trademarks or service marks of Celularity Inc. appearing in this quarterly report. All other trademarks, registered marks and trade names appearing herein are the property of their respective holders. i SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS Some of the statements contained in this quarterly report on Form 10-Q, including the section entitled "Management's Discussion and Analysis of Financial Condition and Results of Operations," constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, or the Securities Act, and Section 21E of the Securities Exchange Act of 1934, or the Exchange Act. Forward-looking statements relate to expectations, beliefs, projections, future plans and strategies, anticipated events or trends and similar expressions concerning matters that are not historical facts. These statements relate to our future events, including our anticipated operations, research, development and commercialization activities, clinical trials, operating results and financial condition. These forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements, to be materially different from any future results, performances or achievements expressed or implied by the forward-looking statements. Forward-looking statements may include, but are not limited to, express or implied statements about: the success, cost, timing and potential indicatio

View Full Filing

View this 10-Q filing on SEC EDGAR